Overview of Respiratory Syncytial Virus (RSV)

Overview of Respiratory Syncytial Virus (RSV)

RSV is a viral infection caused by a member of the Orthopneumovirus genus in the Pneumoviridae family. The virus includes several types, such as human RSV, bovine RSV, and murine pneumonia virus. Human RSV is categorized into two main subgroups—A and B—which differ primarily due to antigenic changes and mutations in the RSV-G gene, as well as broader genomic differences in the RSV-F gene.

Transmission occurs through respiratory droplets from coughing, sneezing, or close contact like kissing. It can also spread by touching contaminated surfaces and then touching the face. RSV remains viable for several hours on hard surfaces, but for a shorter time on soft materials. Children, particularly those in schools or daycare, are highly susceptible to RSV and often pass it on to household members. Nearly all children experience RSV infection by the age of two.

See the full picture—explore our latest infographic now. Click Here : 

https://www.delveinsight.com/infographics/respiratory-syncytial-virus-rsv-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

RSV Epidemiological Segmentation (2020–2034, 7 Major Markets - 7MM)

• Total incident cases

• Age-stratified incident cases

• Severity-specific cases in children

• Severity-specific cases in adults

• Healthcare visit-based incident cases
  
  

Want the full story? Download the complete report now : 

https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

RSV Epidemiology Highlights
In 2023, the number of new RSV cases in the 7MM was estimated at 8.6 million. The United States represented about 56% of these cases. The highest incidence was observed in children under the age of five, who made up nearly half of all reported cases.

RSV Market Overview
In 2023, the RSV market in the 7MM reached a value of approximately USD 1.3 billion.

Market Growth Drivers:

• Increased recognition of RSV as a serious health concern, especially for young children

• Advancements in vaccine research and preventive strategies

• Advocacy groups boosting awareness of RSV risks and prevention

• High demand for effective treatments due to existing unmet needs

• Improvements in early detection and diagnostic methods
  
  

Market Challenges:

• Limited availability of preventive vaccines and options

• Low public awareness, especially among parents

• Difficulty in developing treatments effective across all age groups

• High costs that restrict patient access to therapies

• Slow and complex regulatory pathways for new drug approvals
  
  

Curious about the numbers? Dive into the data with our infographic : 

https://www.delveinsight.com/infographics/respiratory-syncytial-virus-rsv-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Emerging RSV Treatments
Promising therapies in the pipeline include:

• VAC 18193

• mRNA-1345

• And others
  
  

Key Players in the RSV Market
Leading pharmaceutical companies developing RSV-related products include:

• Bavarian Nordic

• GlaxoSmithKline (GSK)

• Janssen

• Sanofi

• AstraZeneca

• Moderna

• And others

See the bigger picture—get the full report. Click Here